Lonafarnib was prioritised by our International Linked Clinical Trials committee in 2020, with the recommendation that further investigative laboratory research was needed to further assess its potential to treat Parkinson’s.
The funding of this Chicago-based research led by Professor Joe Mazzulli, will, it is hoped, give us a better understanding of how lonafarnib can reduce the build-up of the toxic protein alpha-synuclein which is a characteristic of Parkinson’s, and give us the evidence needed to move lonafarnib into clinical testing for people with Parkinson’s.
